You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-CDKN1A (CDKN1A) Antibodies

Full name:
anti-Cyclin-Dependent Kinase Inhibitor 1A Antibodies (CDKN1A)
On are 4 Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A) Antibodies from 2 different suppliers available. Additionally we are shipping CDKN1A Kits (6) and CDKN1A Proteins (2) and many more products for this protein. A total of 12 CDKN1A products are currently listed.
CAP20, CDKI, Cdkn1, CIP1, MDA-6, mda6, P21, p21Cip1, p21WAF, SDI1, Waf1
list all antibodies Gene Name GeneID UniProt
CDKN1A 1026 P38936
Anti-Mouse CDKN1A CDKN1A 12575 P39689

Show all species

Show all synonyms

Most Popular Reactivities for anti-CDKN1A (CDKN1A) Antibodies

Select your species and application

anti-Human CDKN1A Antibodies:

anti-Rat (Rattus) CDKN1A Antibodies:

All available anti-CDKN1A Antibodies

Go to our pre-filtered search.

More Antibodies against CDKN1A Interaction Partners

Human Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A) interaction partners

  1. Data show CGK733 induced microtubule associated protein LC3B (show MAP1LC3B Antibodies) formation upstream of AMP-activated protein kinase (show PRKAA2 Antibodies) and protein kinase (show CDK7 Antibodies) RNA-like endoplasmic reticulum kinase/CCAAT-enhancer-binding protein homologous protein (show DDIT3 Antibodies) pathways and p21 Cip1 expression.

  2. Data suggest that HOXA-AS2 (show ARSA Antibodies) could be an oncogene (show RAB1A Antibodies) for GC partly through suppressing P21, PLK3 (show PLK3 Antibodies), and DDIT3 (show DDIT3 Antibodies) expression.

  3. Findings suggest that the regulation of c-Myc (show MYC Antibodies) in breast cancer cells is dependent on the molecular subtype, and that beta-catenin (show CTNNB1 Antibodies)-mediated regulation of c-Myc (show MYC Antibodies) and p21 may control the balance of cell death and proliferation in breast cancer.

  4. These findings point to (i) the relevance of CS-related mechanisms in Hodgkin lymphoma , and to (ii) the prognostic value of a simple, reproducible, and low-cost immunohistochemical evaluation of p16(INK4a (show CDKN2A Antibodies)) and p21(CIP1/WAF1) expression.

  5. Plk3 (show PLK3 Antibodies) is involved in the inhibition of cell proliferation and tumorigenesis, which may occur via interactions with p21.

  6. Foxo3 (show FOXO3 Antibodies) circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2 (show CDK2 Antibodies).

  7. prolactin (show PRL Antibodies) activation of Stat5 (show STAT5A Antibodies) results in the formation of a complex between phospho-Stat5 (show STAT5A Antibodies) and BRCA1. Formation of this complex does not interfere with nuclear translocation or binding of BRCA1 to the p21 promoter

  8. the meta-analysis suggested that, in the p21 Ser31Arg polymorphism, Ser (show SIGLEC1 Antibodies)-allele and Ser/Ser (show SIGLEC1 Antibodies) genotype might be risk factors for gastrointestinal tract tumor in Asian populations

  9. Data showed that miR (show MLXIP Antibodies)-423 was up-regulated in colorectal cancer (CRC (show CALR Antibodies)) tissues promoting cell proliferation. Cip1 mediated the function of miR (show MLXIP Antibodies)-423, and its overexpression reversed the augmented effect of miR (show MLXIP Antibodies)-423 on cell proliferation.

  10. This case-control study was designed to analyse the association Single nucleotide polymorphisms (SNPs) of p53 rs1042522, MDM2 rs2279744 and p21 rs1801270 and retinoblastoma (RB) in a Chinese Han population.

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A) interaction partners

  1. Foxo3 (show FOXO3 Antibodies) circular RNA retards cell cycle progression via forming ternary complexes with p21 (show D4S234E Antibodies) and CDK2 (show CDK2 Antibodies).

  2. TFAP2C (show TFAP2C Antibodies) in trophoblasts controls proliferation by repressing Cdkn1a and activating the MAPK (show MAPK1 Antibodies) pathway, further supporting differentiation of glycogen (show GYS1 Antibodies) cells by activating the AKT (show AKT1 Antibodies) pathway

  3. Interaction between ASPM (show ASPM Antibodies) and the Cdk2 (show CDK2 Antibodies)/Cyclin E (show CCNE1 Antibodies) complex regulated the Cyclin (show PCNA Antibodies) activity by modulating its ubiquitination and localization into the nucleus.

  4. we present evidence that VPA administration to mice increases hippocampal p21 (show D4S234E Antibodies) expression, accompanied by DNA demethylation at the distal CpG island.

  5. LKB1 (show STK11 Antibodies) mediates CDKN1A degradation in response to ultraviolet DNA damage.

  6. At high glucose concentrations in vitro, AdipoR1 (show ADIPOR1 Antibodies) regulated the survival of neural stem cells through the p53 (show TP53 Antibodies)/p21 (show D4S234E Antibodies) pathway and the proliferation- and differentiation-related factors of neural stem cells via TLX (show NR2E1 Antibodies).

  7. Phosphorylation of p53 (show TP53 Antibodies) by LRRK2 (show LRRK2 Antibodies) induces p21(WAF1/CIP1) expression and apoptosis.

  8. AMP-18 (show GKN1 Antibodies) appears to act through PI3K/AKT (show AKT1 Antibodies) pathways to increase p21 (show D4S234E Antibodies) phosphorylation, thereby reducing its nuclear accumulation to overcome the antiproliferative effects of TNF-alpha (show TNF Antibodies).

  9. Intense P21 (show D4S234E Antibodies) expression observed in basal and supra-basal layers facing future dental papilla cells, weakly expressed in other basal cells. P21 (show D4S234E Antibodies) is exclusively found in the IEE, supra-IEE and several dental papilla cells in mice.

  10. Deficiency of CDKN1A or both CDKN1A and CDKN1B (show CDKN1B Antibodies) affects the pubertal development of mouse Leydig cells.

CDKN1A Antigen Profile

Antigen Summary

This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene.

Alternative names and synonyms associated with CDKN1A

  • cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) antibody
  • cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a) antibody
  • CAP20 antibody
  • CDKI antibody
  • Cdkn1 antibody
  • CIP1 antibody
  • MDA-6 antibody
  • mda6 antibody
  • P21 antibody
  • p21Cip1 antibody
  • p21WAF antibody
  • SDI1 antibody
  • Waf1 antibody

Protein level used designations for CDKN1A

CDK-interacting protein 1 , CDK-interaction protein 1 , DNA synthesis inhibitor , cyclin-dependent kinase inhibitor 1 , melanoma differentiation associated protein 6 , wild-type p53-activated fragment 1 , melanoma differentiation-associated protein , p21

1026 Homo sapiens
12575 Mus musculus
Selected quality suppliers for anti-CDKN1A (CDKN1A) Antibodies
Did you look for something else?